Reliable acid suppression with pantoprazole contrasts with rapid development of tolerance to ranitidine in healthy individuals

Clinical Drug Investigation

Volumn 21, Issue 4, 2001, Pages 273-279

  Teyssen, S ^a   Singer, M V ^a   Pfutzer R ^a   Heinze, H ^b   Fischer, R ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b ALTANA PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIN; PANTOPRAZOLE; RANITIDINE;

ACID SECRETION; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG TOLERANCE; FEMALE; GASTRIN BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ACID SECRETION; TACHYPHYLAXIS;

EID: 0035055960     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200121040-00005     Document Type: Article

References (35)

1. Continuing development of acid pump inhibitors: Site of action of pantoprazole
2. 2-receptors
3. Optimizing acid suppression for treatment of acid-related diseases
4. Review article: The pharmacological inhibition of gastric acid secretion - Tolerance and rebound
5. 2-receptor antagonists. An overview
6. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine
7. Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole
8. Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders
9. Appropriate acid suppression for the management of gastro-oesophageal reflux disease
10. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression
11. The relationship between suppression of acidity and gastric ulcer healing rates
12. Acid suppression in duodenal ulcer: A meta-analysis to define optimal dosing with antisecretory drugs
13. The use of non-parametric methods in the statistical analysis of the two-period change-over design
14. Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing?
15. Efficacy of primed infusions with high dose ranitidine and omeprazole to maintain high intragastric pH in patients with peptic ulcer bleeding: A prospective randomised controlled study
16. Effect of a 28-day therapy with famotidine on blood levels of alcohol and gastrin and intragastric pH in healthy human subjects
17. Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole
18. Effect of repeated oral administration of BY 1023/SK&F 96022 - A new substituted benzimidazole derivative - On pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man
19. Effect of once daily intravenous and oral omeprazole on 24-hour intragastric acidity in healthy subjects
20. +- ATPase activity
21. 2-antagonist treatment
22. 2-receptor blockade in normal subjects and duodenal ulcer patients
23. Acid suppression: Optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome
24. pH dependence of acid secretion and gastrin release in normal and ulcer subjects
25. Dose-response of pantoprazole 20, 40 and 80 mg on 24-hour intragastric pH and serum gastrin in man
26. Omeprazole in the long-term management of patients with acid-related diseases resistant to ranitidine
27. 24-Hour intragastric acidity and plasma gastrin during long-term treatment with omeprazole or ranitidine in patients with reflux esophagitis
28. Serum gastrin levels during long-term omeprazole treatment
29. Pantoprazole: A new proton pump inhibitor in the management of upper gastrointestinal disease
30. The Second Canadian Consensus Conference on the Management of Patients with Gastroesophageal Reflux Disease
31. Gastrin and the entero-chromaffin-like cell: An acid update
32. 2 receptors
33. Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders
34. Does fasting serum gastrin predict gastric acid suppression in patients on proton-pump inhibitors?
35. Review article: Current perspectives on hyper-gastrinaemia and enterochromaffin-like-cell hyperplasia